marked.bio

Company

Beijing InnoCare Pharma Tech

2 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

gunagratinib 1

Trials

2 of 6 trials shown

  1. Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

    Recruiting Phase 1/2 Beijing InnoCare Pharma Tech Started 2022Primary completion 2027-12 NCT05745623

    ICP-723

    …ients with advanced solid tumors or primary central nervous system (CNS) tumors harboring NTRK gene fusions as detected by the designated central laboratory, who received no previous NTRK inhibitor…

    NTRK1/2/3 fusionAdvanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion

  2. A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

    Recruiting Phase 2 Beijing InnoCare Pharma Tech Started 2022Primary completion 2026-05 NCT05678270

    gunagratinib

    FGFR2 fusion /rearrangement as confirmed by the central laboratory.

    FGFR2 fusion or rearrangementStatus may be outdated, last updated 2024-02-07Intrahepatic Cholangiocarcinoma (ICC)